The Hepatotoxicity of Antifungal Medications in Bone Marrow Transplant Recipients
Open Access
- 1 August 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (3) , 301-307
- https://doi.org/10.1086/431586
Abstract
Background. Systemic antifungal medications can be lifesaving but can also have important toxicities. With a number of new antifungal drugs being intKeywords
This publication has 28 references indexed in Scilit:
- Diagnosis of fungal infection: new technologies for the mycology laboratoryTransplant Infectious Disease, 2002
- Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997Clinical Infectious Diseases, 2001
- Aspergillosis Case-Fatality Rate: Systematic Review of the LiteratureClinical Infectious Diseases, 2001
- Mycoses in the transplanted patientMedical Mycology, 2000
- Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 1999
- Incidence and risk factors for invasive fungal infections in allogeneic BMT recipientsBone Marrow Transplantation, 1997
- Efficacy and Safety of Fluconazole Prophylaxis for Fungal Infections after Marrow Transplantation--A Prospective, Randomized, Double-Blind StudyThe Journal of Infectious Diseases, 1995
- A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without NeutropeniaNew England Journal of Medicine, 1994
- NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosisThe American Journal of Medicine, 1994
- A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow TransplantationNew England Journal of Medicine, 1992